盘龙药业: 半年报监事会决议公告

Group 1 - The supervisory board of Shanxi Panlong Pharmaceutical Group Co., Ltd. held its 21st meeting, confirming the legality and accuracy of the company's 2025 semi-annual report [1][2] - The supervisory board unanimously agreed that the company has properly stored and utilized its raised funds, ensuring no violations or damages to shareholders' interests [2] - The profit distribution plan for the first half of 2025 was deemed compliant with relevant laws and beneficial for the company's long-term stability, without harming shareholders' interests [2]